Europe - Euronext Milan - BIT:1ALC - CH0432492467 - Common Stock
The current stock price of 1ALC.MI is 67.5 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ESL.DE | ESSILORLUXOTTICA | 45.27 | 144.04B | ||
| 1EL.MI | ESSILORLUXOTTICA | 44.95 | 143.02B | ||
| EL.PA | ESSILORLUXOTTICA | 44.93 | 142.97B | ||
| GBT.PA | GUERBET | 29.51 | 227.52M | ||
| ALCJ.PA | CROSSJECT | N/A | 123.80M | ||
| AFME.PA | AFFLUENT MEDICAL SA | N/A | 61.39M | ||
| SVS.MI | SVAS BIOSANA SPA | 6.68 | 47.49M | ||
| PTP.DE | PENTIXAPHARM HOLDING AG | N/A | 34.52M |
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,599 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
ALCON INC
Rue Louis d'Affry 6
Fribourg FRIBOURG CH
Employees: 25599
Phone: 41589113800
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg and currently employs 25,599 full-time employees. The company went IPO on 2019-04-09. The firm research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The firm operates in 60 countries and serves consumers and patients in over 140 countries.
The current stock price of 1ALC.MI is 67.5 EUR. The price increased by 5.47% in the last trading session.
ALCON INC (1ALC.MI) has a dividend yield of 0.46%. The yearly dividend amount is currently 0.23.
1ALC.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for ALCON INC (1ALC.MI) is 25.96. This is based on the reported non-GAAP earnings per share of 2.6 and the current share price of 67.5 EUR.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1ALC.MI.
ALCON INC (1ALC.MI) currently has 25599 employees.
ChartMill assigns a technical rating of 2 / 10 to 1ALC.MI.
ChartMill assigns a fundamental rating of 5 / 10 to 1ALC.MI. 1ALC.MI has an average financial health and profitability rating.
Over the last trailing twelve months 1ALC.MI reported a non-GAAP Earnings per Share(EPS) of 2.6. The EPS decreased by -0.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.7% | ||
| ROA | 3.42% | ||
| ROE | 4.85% | ||
| Debt/Equity | 0.23 |
20 analysts have analysed 1ALC.MI and the average price target is 92.25 EUR. This implies a price increase of 36.67% is expected in the next year compared to the current price of 67.5.
For the next year, analysts expect an EPS growth of 1.39% and a revenue growth 5.28% for 1ALC.MI